Plaintiff

Ares Trading SA

4 cases as plaintiff.

Cases: 4
Active: 0; 4 closed
Filed: 2022
Top venue: D Del; 4 cases

Also appears as a defendant in 1 case → View as defendant

Watchlist

Get alerted when Ares Trading SA sues again.

Email-only, free, anonymous. We'll notify you when Ares Trading SA files another patent-infringement lawsuit. One-click unsubscribe from any alert.

Merck KGaA et al. v. Hopewell Pharma Ventures, Inc. et al.

stayed

Docket:: 1:22-cv-01365-GBW-CJB
Court:: D. Del.
Filed:: 2022-10-17

Patents:10849919 7713947 8377903

π Merck KGaA π Merck Serono SA π Ares Trading SA Δ Hopewell Pharma Ventures, Inc.Δ Aurobindo Pharma USA, Inc.Δ Aurobindo Pharma Ltd.Δ Apotex Inc.Δ Apotex Corp.

Original complaint asserted '919; plaintiffs ceased asserting the '919 patent against all defendants. The consolidated case was later globally stayed pending IPR appeals on the '947 and '903 patents.

Merck KGaA et al. v. Accord Healthcare, Inc.

stayed

Docket:: 1:22-cv-00974-GBW
Court:: D. Del.
Filed:: 2022-07-25

Patents:10849919 7713947 8377903

π Merck KGaA π Merck Serono SA π Ares Trading SA Δ Accord Healthcare, Inc.

First Amended Complaint (ANDA No. 216813) asserted the '947, '903, and '919 patents. The case was stayed within the same global stay; there was no separate '919 outcome.

Merck KGaA et al. v. Aurobindo Pharma USA, Inc. et al.

consolidated

Docket:: 1:23-cv-00039-GBW-CJB
Court:: D. Del.

Patents:10849919 7713947 8377903

π Merck KGaA π Merck Serono SA π Ares Trading SA Δ Aurobindo Pharma USA, Inc.Δ Aurobindo Pharma Ltd.

Consolidated into 22-1365. The '919 patent was asserted in the original complaint but dropped; the consolidated case involved the '947 and '903 patents.

Merck KGaA et al. v. Apotex Inc. et al.

consolidated

Docket:: 1:23-cv-00655-GBW-CJB
Court:: D. Del.

Patents:10849919 7713947 8377903

π Merck KGaA π Merck Serono SA π Ares Trading SA Δ Apotex Inc.Δ Apotex Corp.

Consolidated into 22-1365 (except trial). The '919 patent was asserted in the original complaint but dropped; Apotex's ANDA was approved Nov. 24, 2025. The consolidated case involved the '947 and '903 patents.